君实生物 · Junshi Biosciences
← News archive

· Regulatory update

China approves two additional indications for ongericimab

Junshi announced the approval in China of two supplemental applications for its PCSK9 antibody ongericimab.

The approvals cover additional patient populations, including adults with heterozygous familial hypercholesterolemia. The company release describes the populations and conditions of use for both indications.

Read the full company release